Premium
Changes in the first line H elicobacter pylori eradication rates using the triple therapy–a multicenter study in the T okyo metropolitan area (Tokyo Helicobacter pylori study group)
Author(s) -
Kawai Takashi,
Takahashi Shin'ichi,
Suzuki Hidekazu,
Sasaki Hitoshi,
Nagahara Akihito,
Asaoka Daisuke,
Matsuhisa Takeshi,
Masaoaka Tatsuhiro,
Nishizawa Toshihiro,
Suzuki Masayuki,
Ito Masayoshi,
Kurihara Naoto,
Omata Fumio,
Mizuno Shigeaki,
Torii Akira,
Kawakami Kohei,
Ohkusa Toshifumi,
Tokunaga Kengo,
Mine Tetsuya,
Sakaki Nobuhiro
Publication year - 2014
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12796
Subject(s) - medicine , lansoprazole , helicobacter pylori , rabeprazole , omeprazole , urea breath test , gastroenterology , clarithromycin , proton pump inhibitor , amoxicillin , peptic , gastritis , chronic gastritis , breath test , regimen , peptic ulcer , antibiotics , helicobacter pylori infection , microbiology and biotechnology , biology
Background and Aim H elicobacter pylori ( H . pylori ) infection is a strong risk factor for the development of gastric cancer. In 2013, the J apanese government approved H . pylori eradication therapy in patients with chronic gastritis as well as peptic ulcer. However, the continuing decline in eradication rates for first‐line H . pylori eradication therapies is an urgent problem. In this study, we investigated changes in the first‐line eradication rate from 2001 to 2010. Methods Eradication rates for 7‐day triple therapy [proton pump inhibitor (rabeprazole 20 mg, lansoprazole 60 mg, or omeprazole 40 mg) + amoxicillin 1500 mg + clarithromycin ( CAM ) 400 or 800 mg, daily] were collated from 14 hospitals in the T okyo metropolitan area. The urea breath test was used for the evaluation of eradication. The cut‐off value was less than 2.5%. Results The yearly eradication rates (intention to treat/per protocol) were 78.5/79.5% (2001, n = 242), 71.2%/72.9% (2002, n = 208), 67.8%/70.5% (2003, n = 183), 75.6%/84.6% (2004, n = 131), 56.4%/70.5% (2005, n = 114), 70.5%/75.8% (2006, n = 271), 67.4%/82.0% (2007, n = 135), 64.0%/76.3% (2008, n = 261), 60.5%/74.3% (2009, n = 329), and 66.5%/78.8% (2010, n = 370), respectively. Examination of eradication rates according to CAM dosage revealed an eradication rate of 65.6% (383/584) for CAM 400 mg daily, and 68.5% (1124/1642) for CAM 800 mg daily, with no significant difference seen between dosages. Conclusion In recent years, eradication rates for first‐line triple therapy have obviously decreased, but no noticeable decrease has occurred after 2001.